The fact that ADHD is one of the most commonly diagnosed conditions for children in the United States, coupled with the fact that adults recently overtook children as the industry's largest market share, provided a boon to the ADHD Medication Manufacturing industry. Healthcare reform will enable more children to access behavioral health services, resulting in more patients being diagnosed with ADHD earlier and treated. Over the five years to 2022, industry revenue is forecast to grow. Due to the American Psychiatric Association establishing guidelines for diagnosing ADHD in adults in 2013, usage rates for ADHD drugs from adults will likely increase over the next five years.
Operators in this industry manufacture medications that treat people with attention deficits, such as attention deficit disorder (ADD) and attention deficit hyperactivity disorder (ADHD).
This report covers the scope, size, disposition and growth of the industry including the key sensitivities and success factors. Also included are five year industry forecasts, growth rates and an analysis of the industry key players and their market shares.